The company's financial results have been fairly strong, contributing to its year-to-date performance. However, another factor behind Gilead Sciences' run is its important regulatory progress, which has improved its lineup of approved drugs. That's all well and good, but after climbing by almost 30% this year, are Gilead's shares still attractive? Over the past few years, Gilead Sciences has experienced declining sales from its coronavirus medicine, Veklury. The company's financial results have sometimes been mixed as a result, but things are trending up for the biotech giant .
POLARIS INSIGHTS